Enzo Biochem ENZ unveils its next round of earnings Tuesday. Get prepared with Benzinga's ultimate preview for Enzo Biochem's Q2 earnings.
Earnings and Revenue
Enzo Biochem EPS is expected to be around a loss of 1 cent, according to sell-side analysts. Sales will likely be near $27.35 million.
In the same quarter last year, Enzo Biochem reported a loss per share of 2 cents on revenue of $26.26 million. If the company were to report inline earnings when it publishes results Tuesday, sales would be up 4.15 percent on a year-over-year basis.
Enzo Biochem's reported EPS has stacked up against analyst estimates in the past like this:
Quarter | Q1 2018 | Q4 2017 | Q3 2017 | Q2 2017 |
EPS Estimate | -0.01 | -0.02 | -0.03 | -0.04 |
EPS Actual | -0.01 | -0.04 | 0 | -0.02 |
Stock Performance
Over the last 52-week period, shares are up 6.52 percent. Given that these returns are generally positive, long-term shareholders are probably satisfied going into this earnings release.
Over the past 90 days, analysts have adjusted their estimates higher for EPS and revenues. The popular rating by analysts on Enzo Biochem stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.
Conference Call
Enzo Biochem's Q2 conference call is scheduled to begin at 8:30 a.m. ET.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.